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Abstract
Background: The EuroQoL 5D (EQ-5D) has been widely used in studies of cardiac disease, but its
measurement properties in this group are not well established. The study aimed to quantify the
relationship between measures commonly used in studies of cardiac disease and the EQ-5D index across
different levels of disease severity.
Methods: Patient-level data from 7 studies of cardiac interventions were used, which included
randomised trials and observational studies. Relationships between the EQ-5D index and commonly used
cardiac measures, Canadian Cardiovascular Society (CCS) angina severity class, treadmill exercise time
(ETT) and scales of the Seattle Angina Questionnaire (SAQ) were examined. Mixed effects linear
regression was used to assess these relationships, with the EQ-5D index as the response.
Results: Study sample sizes ranged from 68 to 2419. Mean baseline EQ-5D index ranged from 0.77 in
patients at diagnosis (95% CI 0.75, 0.78) to 0.43 in patients with advanced disease (95% CI 0.39, 0.48) and
differed significantly across studies (p < 0.001). There was evidence of a ceiling effect in patients at
diagnosis. The minimum clinically important difference of a one minute increase in ETT was associated with
a 0.019 (95% CI 0.014, 0.025) increase in EQ-5D index. One class increase in CCS was associated with a
0.11 (95% CI 0.09, 0.13) decrease in EQ-5D index. A 10 unit increase in SAQ scales was associated with
increases between 0.04 and 0.07 in EQ-5D index (95% CIs 0.03, 0.05 and 0.05, 0.08). Tests of
heterogeneity indicated the EQ-5D-covariate relationships were consistent across levels of disease
severity for ETT and the treatment satisfaction scale of the SAQ, but heterogeneous for age, gender, CCS
angina class and other scales of the SAQ.
Conclusion: The EQ-5D index varies with coronary disease severity. The relationship between the EQ-
5D index and an outcome measure used in cardiac intervention studies, ETT, was consistent across disease
severity levels, but the relationship between demographic variables, CCS angina class and most of the SAQ
scales and the EQ-5D index was heterogeneous for patients with different levels of coronary disease.
Differences in the EQ-5D index associated with clinically important differences in cardiac measures can be
quantified and vary between three important examples - angina class, ETT and SAQ.
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Coronary heart disease (CHD) is common and new treat-
ments for patients in various stages of the disease con-
tinue to be developed and evaluated. Figure 1 shows a
schematic of how patients may move between different
levels of severity of CHD. Patients diagnosed with CHD
can either be managed medically (which can maintain a
similar level of disease to when they were diagnosed),
with a cardiological procedure such as balloon angi-
oplasty/stenting (PCI), or with surgical revascularization
(coronary artery bypass grafting - CABG) [1]. Following
revascularization, the vast majority of patients have a
good symptomatic response, and those patients generally
return to being medically managed. Other patients may
not be suitable for revascularization at the time of diagno-
sis and will progress to refractory angina [2]. A different
group of patients suffering from electrophysiological
problems of the heart may have a defibrillator inserted.
Many of the patients in these different groups could be
susceptible to eventual heart failure, which in selected
patients could lead to heart transplantation (Tx) with or
without the use of a ventricular assist device (VAD) to sup-
port heart function in the interim [3]. As new interven-
tions for cardiac patients with different levels of disease
severity are developed, they are often tested in clinical tri-
als against current treatment options.
Clinical trial-based evaluations of treatments in many
fields, including cardiology, often include cost-effective-
ness, which requires the elicitation of health related qual-
ity of life (HRQoL) from patients in order to calculate
quality-adjusted life years (QALYs). The EuroQoL 5D
(EQ-5D) is a questionnaire that provides a generic meas-
ure of HRQoL [4-6]. Responses from the questionnaire
can be converted to a single health index utility score [7]
and can be used in conjunction with survival data to cal-
culate QALYs. The index ranges from -0.59 to 1 in the UK
[8], where the value for death is 0 and negative index val-
ues represent health states valued worse than death. The
EQ-5D index is widely known and used, and is currently
recommended by the National Institute for Health and
Clinical Excellence as a tool for measuring adult patients'
perception of utility [6,9].
The EQ-5D index has often been used to assess HRQoL
and to calculate QALYs for cost-effectiveness analyses in
trials of interventions in cardiac patients [3,10-12] and
has been found to be valid and reliable in these patients
[13-20]. Ceiling effects of the EQ-5D index where good
health states are poorly discriminated have, however,
been seen in cardiac patients [20]. A recent analysis of the
literature has shown that EQ-5D index scores are variable
in examples of patients with cardiovascular disease (Dyer
M, Goldsmith, K, Sharples, L, Buxton, M: A review of
health utilities using the EQ-5D in studies within the car-
diovascular area, submitted). The review showed that
mean EQ-5D index scores ranged from 0.45 to 0.88, and
0.31 to 0.78 in studies of ischaemic heart disease (IHD)
and heart failure patients, respectively. The review also
showed that many individual studies have looked at the
responsiveness of EQ-5D index to treatment and found
that scores generally increase with improvements after
treatment as measured by Canadian Cardiovascular Soci-
ety (CCS) angina severity class or New York Heart Associ-
ation (NYHA) classification (Dyer M, Goldsmith, K,
Sharples, L, Buxton, M: A review of health utilities using
the EQ-5D in studies within the cardiovascular area, sub-
mitted). Preliminary meta-regression of aggregate data
from these studies showed a large amount of heterogene-
ity in EQ-5D index scores after stratifying for angina class,
which was not explained by different types of disease
(Dyer M, Goldsmith, K, Sharples, L, Buxton, M: A review
of health utilities using the EQ-5D in studies within the
cardiovascular area, submitted).
Consistency in relationships between the EQ-5D index,
patient characteristics and cardiac outcome measures
across different studies/disease severity groups have not
been assessed using patient level data. This study aims to
use individual patient data to assess how the EQ-5D index
varies in cardiac patients with different levels of disease
severity and to explore and quantify the relationship
between the EQ-5D index and both patient characteristics
and outcome measures commonly used in cardiac studies,
such as exercise treadmill time (ETT), CCS angina classifi-
cation and Seattle Angina Questionnaire (SAQ) scales.
Methods
The EQ-5D index
The EQ-5D questionnaire consists of 5 questions covering
the following health domains: mobility, self-care, usual
activity, pain and anxiety/depression [4-6]. Participants
are asked to choose their level of problems in each
domain from three options: no problems, some or mod-
erate problems and severe problems. The questionnaire
also includes a visual analog scale allowing the participant
to rate their current health state from 0-100. The 5 health
domain questions can be used to generate a single index
value or utility by applying societal preference weights to
states of health as elicited by the questionnaire [4-7].
These preference weights and an algorithm for calculating
the EQ-5D index were determined in a UK population
using data from the Measurement and Valuation of
Health survey [7].
Choice of studies
In order to be able to study effects at the patient level, the
data used were limited to those from studies that the
investigators had been involved in, so that the relation-
ship between the EQ-5D index and cardiac outcomePage 2 of 14
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Coronary heart disease (CHD) schematicFigure 1
Coronary heart disease (CHD) schematic. Key: MM - medical management, PCI - balloon angioplasty ± stenting, CABG - 
bypass surgery.
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This was, therefore, an opportunistic sample that was not
obtained through a systematic review. All studies were
conducted in the UK and the UK scoring algorithm for the
EQ-5D index was used.
Studies were further chosen to be able to study patients
across the spectrum of disease by including those that had
collected EQ-5D data from cardiac patients with different
severities of CHD. The relationship between the EQ-5D
index and measures of cardiac outcomes was the primary
focus, so it was also important that the studies used meas-
ured the cardiac outcomes of interest, including ETT, CCS
angina class and the SAQ, which are further described
below. Some studies collected NYHA rather than CCS.
The relationship between the EQ-5D index and the Short
Form 6D (SF-6D), another utility measure used in cost-
effectiveness analysis [21], was also studied. This latter
relationship was not of direct interest as it has been stud-
ied previously for patients with other types of diseases
[22] and the focus was on the relationship between
patient characteristics and the EQ-5D index, not that
between different measures of HRQoL. The aim in study-
ing the SF-6D was both to compare our results to previous
findings, and to quantify the relationship in cardiac
patients for completeness.
The study includes secondary analysis of results from a
range of clinical trials. All primary clinical trials had ethi-
cal approval from Local Research Ethics committees
between 1993 and 2001.
Cardiac outcome measures
The ETT is a validated clinical test used to assess suspected
or known CHD. The test follows the Bruce protocol which
requires walking on a treadmill at a given speed and with
a given grade, both of which increase through three stages
[23]. The modified protocol uses a constant lower speed
and lower grades (all 1.7 mph with: Stage 1 - 0% grade;
Stage 2 - 5% grade; Stage 3, which is equivalent to Stage 1
in the regular Bruce protocol - 10% grade), and is often
used in patients that are elderly, sedentary, or have known
heart disease.
The CCS is a rating scale for stable angina [24]. It ranges
from 0, meaning no symptoms, to Class IV for the worse
symptoms [See Additional File 1]. The NYHA is a more
general cardiac disease rating scale, which is similar to
CCS, but not completely consistent with it [See Additional
File 1] [25].
The SAQ consists of 11 questions that can be converted
into 5 scales assessing functional status for patients with
angina: exertional capacity (ECS), anginal stability (ASS),
anginal frequency (AFS), disease perception (DPS) and
treatment satisfaction (TSS) [26]. The SAQ has been vali-
dated and widely used in studies of patients with CHD
[26,27].
Studies used for the analysis
Seven studies of cardiac interventions conducted in the
UK were used. The studies are summarized in Figure 1 and
Table 1. Patients ranged from those undergoing imaging
for suspected coronary disease (diagnosis stage) to those
with severe disease. Using studies in different types of
patients allowed us to examine relationships at different
stages of disease (Figure 1 and Table 1). We were also able
to study effects in patients having different treatments by
dividing observations into different disease/treatment
groups using data gathered within the studies at different
time intervals (Table 1). Age and gender were recorded for
all studies at study entry. The studies included:
Cost-effectiveness of functional cardiac testing in the diag-
nosis and management of CHD (CECaT) [12]: a ran-
domised controlled trial (RCT) of coronary disease
diagnostic methods in patients presenting for angiogra-
phy. The EQ-5D index, ETT, CCS, SAQ and SF-6D were
measured at randomisation, 6 months post-treatment and
18 months post-randomisation. Diagnostic methods were
randomised, not treatments; treatments were given as part
of routine patient management. The treatment options
were medical management (MM), PCI or CABG. The first
treatment a patient had was used to classify them into one
of these three treatment groups. Measurements made at
study entry were classed as pre-treatment and the 6 month
post-treatment measurements were taken as treatment
measurements in the three treatment groups.
Appropriateness for coronary revascularization (ACRE)
[1]: a prospective cohort study in patients presenting for
angiography. The EQ-5D index was measured only at the
6 year follow-up point. CCS and SF-6D were measured at
study entry and the 6 year follow-up point. The full SAQ
was administered at study entry, while only the questions
for calculating the ASS and AFS scales of the SAQ were
asked at the 6 year follow-up point. Patients were treated
as indicated clinically with MM, PCI, or CABG. As we were
only using data from the 6 year time point due to the
availability of the EQ-5D index, the ACRE study only con-
tributed post-treatment patients (although baseline infor-
mation has been summarized). Patients could have had
multiple different types of treatment over the 6 year fol-
low-up so patients were classed according to the invasive-
ness of the treatment as follows: if a patient had CABG any
time over the course of the study, they were in the CABG
group, if the patient had only had PCI but not CABG, they
were in the PCI group, and if the patient had neither, they
were in the MM group.Page 4 of 14
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Health and Quality of Life Outcomes 2009, 7:96 http://www.hqlo.com/content/7/1/96Table 1: Summary of studies used and disease/treatment group and treatment variables used in regression models
Name Short 
form
Inclusion/Exclusion 
Criteria
Study type Study size Cardiac 
subgroup
Disease/
treatment 
groups 
(random 
effect)
Treatment
Cost-effectiveness 
of functional cardiac 
testing in the 
diagnosis and 
management of 
CHD [12]
CECaT I: established or 
suspected CHD 
referred for 
angiography
E: recent MI, 
revascularization, 
urgent need for 
revascularization, 
contraindications to 
study tests
Diagnosis/
management 
(RCT)
898 Coronary disease 
diagnosis
CECaT baseline
CECaT MM
CECaT PCI
CECaT CABG
Pre-treatment
MM
PCI
CABG
Appropriateness for 
coronary 
revascularization [1]
ACRE I: Consecutive patients 
having coronary 
angiography
E: None
Diagnosis/
management 
(cohort)
2419 Coronary
revascularization
ACRE MM
ACRE PCI
ACRE CABG
MM
PCI
CABG
Implantable 
Cardioverter 
Defibrillator (ICD) 
therapy in different 
patient groups [28]
ICD I: patients implanted 
with an ICD at 
Papworth or Liverpool 
hospitals between 1991 
and 1999 and a random 
sample of those 
implanted in 2000 and 
2001
Diagnosis/
management 
(cohort)
229 Cardiac 
arrythmias
ICD ICD
Percutaneous 
myocardial 
revascularization 
(PMR) compared to 
continued medical 
therapy [29]
PMR I: angina refractory to 
medication or 
revascularization
E: implanted devices, 
significant comorbidity, 
contraindications to 
study treatments
Angina (RCT) 73 Angina PMR Pre-
treatment*
MM
PMR
Transmyocardial 
laser 
revascularization 
(TMR) compared to 
continued medical 
therapy [30]
TMR I: angina refractory to 
medication or 
revascularization
E: implanted devices, 
significant comorbidity, 
contraindications to 
study treatments
Angina (RCT) 188 Angina TMR baseline
TMR MM
TMR
Pre-
treatment*
MM
TMR
Spinal cord 
stimulation (SCS) 
compared to PMR 
[31]
SPiRiT I: angina refractory to 
medication or 
revascularization
E: implanted devices, 
significant comorbidity, 
contraindications to 
study treatments
Angina (RCT) 68 Angina SPiRiT baseline
PMR
SCS
Pre-
treatment*
PMR
SCS
Evaluation of 
ventricular assist 
devices (VAD) 
patients compared 
to patients on 
transplant waiting 
list (Tx WL) [3]
Tx WL I: a sample of patients 
listed for transplant 
between April 2002 
and December 2004
Heart failure 
(cohort)
47 Heart failure Tx WL Pre-
treatment*Page 5 of 14
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different patient groups (ICD) [28]: a cross-sectional
study in a cohort of patients implanted with an ICD at one
of two centres between 1991 and the end of 2001. Sixty-
nine percent of the patients that had an ICD implant - all
of those still alive who were implanted between 1991 and
1999 and a random sample of those still alive who were
implanted in 2000 and 2001 - were sent the EQ-5D ques-
tionnaire, with a 73% response rate (229 patients).
Because patients had been implanted over a span of time,
the EQ-5D measurement was made at variable times post-
implant. This measurement was considered to be a treat-
ment measurement for ICD and pre-treatment measure-
ments were not available. NYHA was collected from
patient notes, just before or at implant.
Percutaneous myocardial revascularization compared to
continued medical therapy (PMR) [29]: a RCT of PMR for
refractory angina not relieved by medical management.
Patients were randomised to receive PMR or MM and were
followed up at 3, 6 and 12 months. The EQ-5D index,
ETT, CCS, SAQ and SF-6D were measured at all follow-up
points. Measurements made at study entry were classed as
pre-treatment. Measurements made 12 months post-sur-
gery in the PMR group, and post-assessment in the MM
group, were taken as treatment measurements for PMR
and MM.
Transmyocardial laser revascularization compared to con-
tinued medical therapy (TMR) [30]: a RCT of TMR for
refractory angina not relieved by medical management.
Patients were randomised to receive TMR or MM and were
followed up at 3, 6 and 12 months. The EQ-5D index,
ETT, CCS and SF-6D were measured at all follow-up
points. Measurements made at study entry were classed as
pre-treatment. Measurements made 12 months post-sur-
gery in the TMR group, and post-assessment in the MM
group, were taken as treatment measurements for TMR
and MM.
Spinal cord stimulation (SCS) compared to PMR (SPiRiT)
[31]: an RCT of PMR versus SCS for refractory angina not
relieved by medical management. Patients were ran-
domised to receive PMR or SCS and were followed up at
3, 12 and 24 months. The EQ-5D index, ETT, CCS, SAQ
and SF-6D were measured at all follow-up points. Meas-
urements made at study entry were classed as pre-treat-
ment. Measurements made 12 months post-treatment in
the PMR and SCS groups were taken as treatment meas-
urements for these two groups.
Evaluation of ventricular assist devices (VAD) patients
compared to patients on transplant waiting list (Tx WL)
(EVAD) [3]: an observational cohort study - evaluation of
VADs in heart failure patients and a comparison group of
patients on the Tx WL. In this case, measurements taken in
the waiting list group pre-transplantation were classed as
pre-treatment. Measurements taken in the VAD group pre-
transplantation were taken as treatment measurements
for the VAD group. Post-transplantation measurements in
both groups in the subset of patients that underwent
transplantation were taken as treatment measurements
for transplantation (Tx). Measurements of EQ-5D, NYHA
and SF-6D were taken at several time points, so the earliest
one after acceptance on to the transplant list, implant with
a VAD, or Tx, was used.
Statistical analysis
The EQ-5D index and other continuous variables were
summarized using the mean and standard deviation and
boxplots. Categorical variables were summarized using
frequencies and proportions. The difference in baseline
EQ-5D index across studies was examined using a general
linear model with the EQ-5D index as the outcome and
study as the predictor using only data gathered pre-treat-
ment (at study entry).
General linear mixed models were used to assess the rela-
tionship between the EQ-5D index and a series of explan-
atory variables, allowing for heterogeneity across the
disease/treatment groups, which are described above and
in Table 1. In each model EQ-5Dij for patient j (j = 1, ...,
ni) in disease/treatment group i (i = 1,..., 20) was used.
Not all 20 groups had all explanatory variables, so i varied
depending on the number of groups who had the given
variable available. The explanatory variables of primary
interest were age, sex, ETT, CCS and the scales of the SAQ.
SF-6D was also studied. A separate analysis was under-
VAD I: all patients with 
VADs implanted as part 
of NSCAG funded 
program between April 
2002 and December 
2004
Heart failure 
(cohort)
35 Heart failure VAD
Post-tx 
(post-transplant)
VAD
Tx
Key: CHD - coronary heart disease, I - inclusion criteria, E - exclusion criteria, MI - myocardial infarction, RCT - randomised controlled trial, MM - 
medical management, PCI - balloon angioplasty/stenting, CABG - coronary artery bypass graft, NSCAG - National Specialist Commissioning 
Advisory Group
*NB: Pre-treatment for that study, but these patients will not be treatment naïve.
Table 1: Summary of studies used and disease/treatment group and treatment variables used in regression models (Continued)Page 6 of 14
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the SAQ and the SF-6D were centred at their mean value
(for age, mean age at baseline) in the models. For all
explanatory variables, a fixed effect and a Normal random
effect was assumed. In addition, the treatment applied
(pre-treatment, MM, PCI, CABG, ICD, PMR, TMR, SCS,
VAD, Tx) and the study type (Diagnosis/management,
Angina, Heart failure) were included as fixed effects (Table
1). Thus an example of the models would be:
Where:
α0 is a fixed intercept,
α1, α2 and α3 are fixed effects coefficients
βi~N(0, σβ2) are random effects allowing for different age
effects in different disease/treatment groups, and
εij~N(0, σε2) represents residual random error not
explained by the other terms in the model.
After models were fit, the importance of the treatment and
study type fixed effects were tested by removing each var-
iable from each model in turn and using a conditional F-
test [32] to compare models with and without these cov-
ariates.
The minimally important difference (MID) in the EQ-5D
index has been estimated to be between 0.05 - 0.07
[33,34], and was assumed to be 0.05 in the primary anal-
yses of many of the studies used here. Changes in ETT and
CCS that have been considered clinically important differ-
ences in many of the cardiac studies described above were
a one minute change in ETT and a two class change in CCS
class. For SAQ, a 10 unit change is considered clinically
significant [26]. In this study we assessed the change in
EQ-5D index for a ten year increase in age, males versus
females, a one minute increase in ETT, a one class increase
in CCS, a 10 unit increase in the SAQ scales and a 0.1 unit
change in SF-6D as these seemed reasonable quantities
across which to quantify differences in the EQ-5D index.
NYHA data gathered in the ICD and EVAD studies were
not included in modelling because only two studies gath-
ered this data.
Cochran's Q test statistic [35] and the I2 statistic [36] were
used to assess heterogeneity between disease/treatment
groups. In a meta-analysis context, the Cochran's Q allows
for a statistical test of heterogeneity between studies by
taking the sum of the squared differences of each study
from the pooled estimate, weighted in the same way in
which studies were weighted to get the pooled estimate. I2
uses Cochran's Q statistic and the degrees of freedom of
the test to provide a measure of the percent of total varia-
tion that is due to heterogeneity between studies, or here,
between disease/treatment groups.
Results
Study sample sizes ranged between 68 and 2419 (Table
1). The EQ-5D index had more of a ceiling effect in health-
ier patients being diagnosed with heart disease (CECaT
trial) as opposed to those that were symptomatic [See
Additional File 2]. Study subjects were mostly male (69%
or greater, Table 2) and in studies of heart failure the
patients were younger on average than patients in the
other studies (Table 2). Patients being diagnosed with
heart disease had higher EQ-5D index scores, ECS, AFS,
DPS and SF-6D scores and longer exercise times than
patients with more advanced disease at study enrolment
[See Additional Files 2 and 3]. Mean baseline EQ-5D
index was higher in patients at earlier stages of disease
progression, such as those in the CECaT trial (mean EQ-
5D index 0.77), than they were in the patients with later-
stage disease in the other trials (the lowest values were for
patients with angina, for example, 0.43 in the TMR trial,
Table 2). The EQ-5D index differed significantly between
these pre-treatment groups (p < 0.001). The EQ-5D index
score was generally higher post-treatment, with more pro-
nounced ceiling effects [See Additional File 2]. SF-6D
increased slightly and ETT was about the same post-treat-
ment [See Additional File 2]. Most of the scores on the
SAQ scales also increased post-treatment [See Additional
File 3].
Overall there was a small positive non-significant rela-
tionship between age and EQ-5D index with older
patients having higher EQ-5D index scores (Table 3 and
Figure 2 - the forest plots in Figures 2 and 3 show the β
parameter and 95% CI for the given variable for each dis-
ease/treatment group and the pooled effect of the given
variable across the groups). There was, however, signifi-
cant heterogeneity (I2 = 61%) between studies (Table 3).
In the two cohort studies (ACRE and EVAD) there was a
negative relationship whereby EQ-5D index scores
decreased with age, while in the four RCTs (CECaT, TMR,
PMR, Spirit) EQ-5D index scores increased with age.
In the case of gender, male patients had better EQ-5D
index scores than women (0.09 units greater in men on
average, Table 3), but the magnitude of the relationship
was not consistent across disease/treatment groups (Table
3 and Figure 2).
ETT had a small positive relationship with the EQ-5D
index, where the EQ-5D index increased by 0.019 (95%
CI 0.014, 0.025) for each minute increase in ETT (Table 3
and Figure 2). The relationship between ETT and the EQ-
EQ D treatment studytype ageij i ij ij5 0 1 2 3= + + + +( ) +α α α α β ε* * *Page 7 of 14
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across groups (I2 = 36%).
CCS class had a large negative relationship with the EQ-
5D index, with a decrease of 0.11 (95% CI 0.09, 0.13)
with each CCS class increase (Table 3 and Figure 2), and
this relationship exhibited a large amount of heterogene-
ity across disease/treatment groups (Table 3). In general,
there was a stronger relationship between CCS class and
EQ-5D index in angina trials pre-treatment than in the
other disease/treatment groups.
For the SAQ, the EQ-5D index increased by between
approximately 0.04 and 0.07 for a 10 unit increase in the
different SAQ scales (Table 3 and Figure 3). The propor-
tion of variation due to disease/treatment heterogeneity
was high and significant for the scales that measured abil-
ity to exert oneself, anginal frequency and perception of
disease (ECS, AFS and DPS, I2 all equal to 87%), but was
lower for angina severity (ASS) (Table 3). There was no
heterogeneity observed in the relationship between
angina treatment satisfaction (TSS) and the EQ-5D index
(Table 3).
Table 2: Patient characteristics at baseline by study
Characteristic CECaT
n = 898
ACRE
n = 2419
PMR
n = 73
TMR
n = 188
SPiRiT
n = 68
EVAD Tx WL
n = 47
Mean baseline EQ-5D (SD) 0.77 (0.22) --- 0.48 (0.30) 0.43 (0.29) 0.44 (0.30) 0.51 (0.27)
Mean age (SD) 62 (9.4) 60 (9.7) 62 (6.4) 60 (7.6) 64 (8.4) 48 (11.7)
Gender
Male (%) 619 (69) 1701 (70) 69 (95) 169 (90) 60 (88) 39 (83)
Female (%) 279 (31) 718 (30) 4 (5) 19 (10) 8 (12) 8 (17)
Diabetes
Yes (%) 36 (4) 263 (11) N/A 33 (18) 6 (9) N/A
No (%) 862 (96) 2156 (89) N/A 155 (82) 62 (91) N/A
Previous heart attack/angioplasty/
revascularization
Yes (%) 342 (38) N/A 71 (97) 185 (98) 67 (99) N/A
No (%) 556 (62) N/A 2 (3) 3 (2) 1 (1) N/A
CCS or NYHA class*
0 (%) 59 (7) 258 (11) --- --- ---
I (%) 191 (21) 185 (8) --- --- --- ---
II (%) 536 (60) 496 (21) --- --- --- ---
III (%) 100 (11) 211 (9) 48 (66) 143 (76) 47 (69) 18 (38)
IV (%) 12 (1) 639 (26) 25 (34) 43 (23) 21 (31) 7 (15)
Key: CECaT - Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary heart disease study, ACRE - 
Appropriateness for coronary revascularization study, PMR - Percutaneous myocardial revascularization compared to continued medical therapy 
study, TMR - Transmyocardial laser revascularization compared to continued medical therapy study, SPiRiT - Spinal cord stimulation (SCS) 
compared to PMR study, EVAD - Evaluation of ventricular assist devices (VAD) patients compared to patients on transplant waiting list (Tx WL) 
study, EQ-5D - Euroqol 5D, SD - standard deviation, CCS - Canadian Cardiovascular Society angina classification, NYHA - New York Heart 
Association angina classification
*CCS class for all but EVAD groups. In the case where percentages do not sum to 100, it is due to missing values.Page 8 of 14
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Relationship between the EQ-5D index and patient characteristics/clinical outcome measures across diagnosis groupsFigure 2
Relationship between the EQ-5D index and patient characteristics/clinical outcome measures across diagnosis 
groups. Key: CECaT - Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary heart dis-
ease study, BASE - baseline measurements, MM - medical management, ACRE - Appropriateness for coronary revascularization 
study, PCI - percutaneous angioplasty/stenting, CABG - coronary artery bypass graft, ICD - Implantable Cardioverter Defibril-
lator, PMR - Percutaneous myocardial revascularization compared to continued medical therapy study, TMR - Transmyocardial 
laser revascularization compared to continued medical therapy study, SPiRiT - Spinal cord stimulation (SCS) compared to PMR 
study, Tx WL - transplant waiting list, VAD - ventricular assist device, Tx - post heart transplantation, Angina = data from PMR, 
TMR and SPiRiT studies, TRTMT = data from all treatments in Angina studies, Heart failure = TxWL and VAD patients, CCS - 
Canadian Cardiovascular Society angina classification, SF-6D - short form 6D.
 
Health and Quality of Life Outcomes 2009, 7:96 http://www.hqlo.com/content/7/1/96
Page 10 of 14
(page number not for citation purposes)
Relationship between the EQ-5D index and Seattle Angina Questionnaire scales across diagnosis groupsFigure 3
Relationship between the EQ-5D index and Seattle Angina Questionnaire scales across diagnosis groups. Key: 
CECaT - Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary heart disease study, 
BASE - baseline measurements, MM - medical management, PCI - percutaneous angioplasty/stenting, CABG - coronary artery 
bypass graft, PMR - Percutaneous myocardial revascularization compared to continued medical therapy study, SPiRiT - Spinal 
cord stimulation (SCS) compared to PMR study, ECS - exertional capacity scale, ACRE - Appropriateness for coronary revas-
cularization study, ASS - angina severity scale, AFS - anginal frequency scale, TSS - treatment satisfaction scale, DPS - disease 
perception scale.
  
 
Health and Quality of Life Outcomes 2009, 7:96 http://www.hqlo.com/content/7/1/96As expected, there was large positive relationship between
the EQ-5D index and the other generic measure of HRQoL
studied, SF-6D. A large proportion of the variation in the
EQ-5D/SF-6D relationship was due to heterogeneity
across disease/treatment groups (Table 3 and Figure 2).
Study and treatment type fixed effects were important cov-
ariates for almost all of the patient variables of interest
(data not shown), and so were left in all models for con-
sistency.
Discussion
This project utilized data from several different studies of
cardiovascular patients to assess the relationship between
the EQ-5D index and various patient characteristics and
outcomes. Using studies from a range of clinical scenarios
allowed us to assess relationships between the EQ-5D
index and other variables at different cardiac disease
stages and in different treatment groups. A patient-level
analysis such as this has substantially more power to
detect effects than a meta-regression of aggregate results,
and allows effects to be measured with greater precision.
We observed ceiling effects of the EQ-5D index, especially
in cardiac patients in the diagnosis stage of disease, and
also after treatment. Ceiling effects in the EQ-5D index
have been shown in cardiac patients and for other groups
[22,37,38]. Healthier patients, such as those from the
CECaT study, also exhibited weaker associations between
predictor variables and the EQ-5D index in many cases
and the effects differed in general in patients studied as a
cohort (ACRE, ICD, EVAD - patients with heart failure and
transplant recipients) from those in patients selected for
RCTs. Patients included in RCTs are highly selected. There
is some evidence for worse risk profiles [39] and higher
mortality [39,40] in non-participants versus participants
in cardiac trials. Cohorts, on the other hand, tend to be
less exclusive. It could be that patients selected for ran-
domised trials are healthier and are a more homogeneous
group than those included in cohort studies. This could
lead to less variability in the variables of interest in these
patients, and in particular, the ceiling effect may constrain
the variation in EQ-5D index scores. In the patients stud-
ied here, the EQ-5D index scores for the CECaT trial
groups were less variable than those in the comparable
ACRE groups. It has also been noted that there are gaps in
utility scores near the upper limit of 1 for the EQ-5D index
[38], suggesting that the EQ-5D index does not discrimi-
nate well between good health states. The ceiling effect
and decreased sensitivity of the EQ-5D index at the upper
end of the range will need to be kept in mind when stud-
ying patients early in the course of cardiac disease and
patients post-treatment.
EQ-5D index and age
The relationship between the EQ-5D index and age varied
between patient groups, although the pooled effect was
small and not statistically significant. In patients recruited
Table 3: Relationship between variables and the EQ-5D index - pooled effect and heterogeneity from evidence synthesis across studies
Variable Pooled effect (95% CI) Heterogeneity as measured by I2, p-value
Age (10 year increment) 0.02 (-0.01, 0.04) 61%, < 0.001
Sex (Men vs. women) 0.09 (0.04, 0.14) 93%, <0.001
ETT (1 minute increment) 0.019 (0.014, 0.025) 36%, 0.10
CCS (1 class increase) 0.11 (0.09, 0.13) 86%, <0.001
SAQ - ECS (10 unit increment) 0.066 (0.053, 0.079) 87%, <0.001
SAQ - ASS (10 unit increment) 0.039 (0.029, 0.049) 51%, 0.02
SAQ - AFS (10 unit increment) 0.052 (0.039, 0.067) 87%, <0.001
SAQ - TSS (10 unit increment) 0.044 (0.032, 0.056) 0, 0.45
SAQ - DPS (10 unit increment) 0.063 (0.047, 0.079) 87%, <0.001
SF-6D (0.10 unit increment) 0.17 (0.16, 0.19) 83%, <0.001
Key: EQ-5D - EuroQol 5D, I2 - I2 index for quantifying heterogeneity, ETT - Treadmill exercise test, CCS - Canadian Cardiovascular Society angina 
classification, SAQ - Seattle Angina Questionnaire, ECS - exertional capacity scale, ASS - angina severity scale, AFS - anginal frequency scale, TSS - 
treatment satisfaction scale, DPS - disease perception scale, SF-6D - short form 6DPage 11 of 14
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contrary to the effect seen in "normal" populations
[37,41]. In cohort studies (ACRE, EVAD, ICD), the EQ-5D
index decreased with increasing age, as expected. Beyond
the general differences between trial and cohort patients
described above, older patients selected for RCTs may
have better than average quality of life for their age/sex
group, ie trial patients in older age groups may be partic-
ularly heavily selected and would usually exclude those
with co-morbidities. Cohort patients, such as those with
heart failure, were less selected so that they were more like
people in the general population with respect to the rela-
tionship between age and the EQ-5D index.
EQ-5D index and sex
Men had higher EQ-5D index scores than women. In
some population studies, women reported more prob-
lems on the EQ-5D [37,41] than men, but this did not
lead to significantly lower index scores in the UK popula-
tion [8]. Women with CHD have also been shown to score
lower on the disease-specific HRQoL measure, SAQ [42].
There is evidence that women presenting with stable
angina or acute coronary syndromes have higher levels of
risk factors than men, including CCS or NYHA class
[43,44], suggesting women may be presenting later in the
course of disease. This was also shown to be the case in a
trial of ICDs [45]. The relationship between sex and EQ-
5D index was stronger in CECaT study patients after treat-
ment and angina patients on medical management.
Effects were smaller in cohort patients and angina patients
pre-treatment and post-treatment. Most of the variation
(92.9%) across the disease/treatment groups was due to
heterogeneity.
EQ-5D index and ETT
For each minute increase in ETT, there was a 0.019
increase in EQ-5D index. Based on a recommended MID
of 0.05 between health states [33], it seems there is not a
strong relationship between ETT and the EQ-5D index.
The relationship between these two variables was much
more consistent than the relationships with most other
variables across disease/treatment groups. The EQ-5D
assesses mobility but also a number of other elements
contributing to quality of life and so reflects more non-
physical aspects of HRQoL, while ETT is an indicator of
physical limitations, perhaps explaining the small magni-
tude of the relationship.
EQ-5D index and CCS
For CCS angina class, CECaT treatment groups and angina
trials groups treated with routine medical management
showed a smaller relationship between EQ-5D index and
CCS than CECaT and angina groups at study entry and
ACRE treatment groups. As in the case of the other rela-
tionships explored here, this may be partly due to differ-
ent levels of heterogeneity in trial and cohort participants.
In some studies (the angina trials, for example), most
patients were in CCS classes III and IV, meaning less vari-
ability in this measure. There was a relatively strong rela-
tionship between CCS and EQ-5D index. This could be
because CCS is a discrete measure and a one-class change
may correspond to a relatively large difference in func-
tional limitations.
EQ-5D index and SAQ
Increases in the scales of the SAQ, which indicate
improvements in different aspects of angina, were associ-
ated with increases in EQ-5D index greater than the MID
for exertional capacity, anginal frequency and disease per-
ception, while anginal stability and treatment satisfaction
were associated with slightly smaller differences of
approximately 0.04. Taken together, these indicate a rea-
sonably strong relationship between the generic EQ-5D
HRQoL measure and the disease-specific SAQ. For most of
the SAQ scales (and some other variables studied), there
was a smaller relationship between the scale and EQ-5D
index in the PMR MM group. This was a small group with
few low EQ-5D index scores, and this lack of variation
may explain the different results for this group. The ECS
had a smaller relationship with EQ-5D index in the
CECaT groups than in most of the angina groups, perhaps
reflecting greater physical disability in the angina groups
allowing for larger changes in the EQ-5D index. The rela-
tionship between anginal frequency and EQ-5D index was
at, or greater than, the MID for most groups. The effects
were larger in the CECaT CABG group and to some extent
in the ACRE CABG groups and the PMR treatment groups,
perhaps because patients in these groups were treated by
more aggressive means and perceived a large decrease in
anginal episodes soon after treatment. For disease percep-
tion, there was a larger effect for patients in the angina tri-
als, possibly reflecting the specificity of the scale for
angina/concern about having a heart attack, which may be
less relevant for healthier CECaT patients, for example.
This sort of inconsistency in the relationship between
both the CCS and the SAQ and the EQ-5D index across
disease/treatment groups could reflect that while some
cardiac patients suffer from angina, recently diagnosed
patients and heart failure patients are less likely to have
pain from angina at rest or with mild activity. Treatment
satisfaction was not very variable and had a consistent
relationship with the EQ-5D index. The ASS had a similar
relationship with EQ-5D index in most groups, and in
fact, with the PMR MM group removed, heterogeneity in
this measure across disease/treatment groups was lower
and only borderline significant (44%, p = 0.053).
EQ-5D index and SF-6D
The relationship between EQ-5D index and SF-6D in
angina patients was explored for completeness, and wasPage 12 of 14
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same purpose. There was an increase of 0.17 in EQ-5D
index for each 0.10 unit increase in SF-6D. This relation-
ship has been explored before for patients in different dis-
ease groups using ordinary linear regression and with SF-
6D as the outcome [22], and when applying a similar
model to our data, we obtained a similar result (data not
shown). There was a large amount of heterogeneity in the
relationship across disease/treatment groups, which was
not necessarily expected given that these are both compos-
ite measures of HRQoL. It has been previously noted,
however, that there are differences between these two
measures [20,22,38].
Limitations
A limitation of the study is its focus on patients recruited
to randomised trials. While this does not affect the inter-
nal validity of the results, it may limit their generalisabil-
ity to the overall population with CHD. Secondly, CCS
class was studied in models as a continuous variable,
whereas it is a discrete measure. This could be a reason for
the large effect size of CCS. This was necessary in part
because there were few or no patients in the lower CCS
classes in studies in patients with advanced disease.
Thirdly, differences by sex were difficult to assess sepa-
rately for some disease/treatment groups, angina in partic-
ular, because there was a small proportion of women in
many of the studies, so further work could be done in
studies with more women to assess the robustness of the
estimate of the relationship between sex and EQ-5D index
in cardiac patients. Finally, we were not able to assess the
relationship between other measures such as the Health
Utilities Index or the Minnesota Living with Heart Failure
score and the EQ-5D index as these are not generally used
in the UK and were not therefore available in the datasets
that were used.
Conclusion
We have used individual patient level data to show that
the EQ-5D index decreases as cardiac disease severity
increases and that the EQ-5D index has a ceiling effect in
patients with mild CHD and after treatment. The EQ-5D
index has a relatively strong relationship across different
levels of CHD severity with sex, the scales of the SAQ and
CCS angina severity class and a smaller relationship with
age and ETT. The variation seen in the relationship
between the EQ-5D index and these variables, with the
exception of the ETT and treatment satisfaction measured
by SAQ, is in large part due to heterogeneity between
groups of patients with different levels of CHD severity.
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